Orchestra BioMed Holdings is a biomedical company focused on developing therapeutic products for in procedure-based medicine. Co.'s primary product candidates include Virtue® Sirolimus AngioInfusion Balloon for the treatment of artery disease and BackBeat Cardiac Neuromodulation Therapy for the treatment of hypertension. The OBIO average annual return since 2020 is shown above.
The Average Annual Return on the OBIO average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OBIO average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OBIO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|